Elevation of serum KL-6 mucin levels in patients with cholangiocarcinoma

Hepato-Gastroenterology

Volumn 55, Issue 88, 2008, Pages 2000-2004

  Xu, Huanli ^a,b   Inagaki, Yoshinori ^a   Tang, Wei ^a,b   Guo, Qian ^a   Wang, Fengshan ^b   Seyama, Yasuji ^a   Midorikawa, Yutaka ^a   Gai, Ruoyan ^a   Kokudo, Norihiro ^a   Sugawara, Yasuhiko ^a   Nakata, Munehiro ^c   Makuuchi, Masatoshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b SHANDONG UNIVERSITY   (China)

^c TOKAI UNIVERSITY   (Japan)

Author keywords

Cholangiocarcinoma; KL 6 mucin; Liver cancer; Serum

Indexed keywords

MUCIN 1; MUCIN KL 6; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SEROLOGY;

EID: 60849103518     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. The Liver Cancer Study Group of Japan: Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg 1990; 211:277-287.
2. Allen RA, Lisa JR: Combined liver cell and bile duct carcinoma. Am J Pathol 1949; 25:647-655.
3. Goodman ZD, Ishak KG, Langloss JM, Sesterhenn IA, Rabin L: Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study. Cancer 1985; 55:124-135.
4. Di Bisceglie AM: Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology 2004; 127: S104-107.
5. Bendardaf R, Lamlum H, Pyrhonen S: Prognostic and predictive molecular markers in colorectal carcinoma. Anticancer Res 2004; 24:2519-2530.
6. Sasaki M, Nakanuma Y, Kim YB: Characterization of apomucin expression in intrahepatic cholangiocarcinomas and their precursor lesions: an immunohistochemical study. Hepatology 1996; 24:1074-1078.
7. Higashi M, Yonezawa S, Ho JJL, Tanaka S, Irimura T, Kim YS et al: Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. Hepatology 1999; 30:1347-1355.
8. Matsumura N, Yamamoto M, Aruga A, Takasaki K, Nakano M: Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma. Cancer 2002; 94:1770-1776.
9. Yuan SF, Li KZ, Wang L, Dou KF, Yan Z, Han W et al: Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue. World J Gastroenterol 2005; 11:4661-4666.
10. Kohno N: Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis. J Med Invest 1999; 46:151-158.
11. Kohno N, Akiyama M, Kyoizumi S, Hakoda M, Kobuke K, Yamakido M: Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol 1988; 18:203-216.
12. Tang W, Inagaki Y, Kokudo N, Guo Q, Seyama Y, Nakata M et al: Aberrant expression of KL-6 in carcinoma of the ampulla of Vater: association with cancer progression. World J Gastroenterol 2005; 11:5450-5454.
13. Guo Q, Tang W, Inagaki Y, Midorikawa Y, Kokudo N, Sugawara Y et al: Clinical significance of subcellular lacalization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues. World J Gastroenterol 2006; 12:54-59.
14. Tang W, Guo Q, Qu X, Inagaki Y, Seyama Y, Midorikawa Y et al: KL-6 mucin is a useful immunohistochemical marker for cholangiocarcinoma. Oncol Rep 2007; 17:737-742.
15. Zhang K, Tang W, Qu X, Guo Q, Inagaki Y, Seyama Y et al: KL-6 mucin in metastatic liver cancer tissues from primary colorectal carcinoma. Hepato-Gastroenterology in press.
16. The general rules for the clinical and pathological study of primary liver cancer. 2nd edition. Tokyo: Liver Cancer Study Group of Japan; 2003.
17. Okuda K, Nakanuma Y, Miyazaki M: Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J Gastroenterol Hepatol 2002; 17: 1049-1055.
18. Nomura F, Ohnishi K, Tanabe Y: Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Cancer 1989; 64:1700-1707.
19. Yamashita F, Tanaka M, Satomura S, Tanikawa K: Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology 1996; 111:996-1001.
20. Okuda H, Obata H, Nakanishi T, Furukawa R, Hashimoto E: Production of abnormal prothrombin (des-gamma-carboxy prothrombin) by hepatocellular carcinoma. A clinical and experimental study. J Hepatol 1987; 4:357-363.
21. Maeda T, Adachi E, Kajiyama K, Sugimachi K, Tsuneyoshi M: Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features. Hum Pathol 1995; 26:956-64.
22. Nakeeb A, Lipsett PA, Lillemoe KD, Fox-Talbot MK, Coleman J, Cameron JL et al: Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma. Am J Surg 1996; 171:147-53.
23. Qin XL, Wang ZR, Shi JS, Lu M, Wang L, He QR: Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA. World J Gastroenterol 2004; 10:427-432.
24. Gardini A, Corti B, Fiorentino M, Altimari A, Ercolani G, Grazi GL, et al: Expression of connective tissue growth factor is a prognostic marker for patients with intrahepatic cholangiocarcinoma. Dig Liver Dis 2005; 37:269-274.
25. Park BK, Paik YH, Park JY, Park KH, Bang S, Park SW et al: The clinicopathologic significance of the expression of vascular endothelial growth factor-C in intrahepatic cholangiocarcinoma. Am J Clin Oncol 2006; 29:138-142.
26. Boonla C, Wongkham S, Sheehan JK, Wongkham C, Bhudhisawasdi V, Tepsiri N et al: Prognostic value of serum MUC5AC mucin in patients with cholangiocarcinoma. Cancer 2003; 98:1438-1443.
27. Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M: New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 1989; 96:68-73.
28. Hamada H, Kohno N, Hiwada K: A new serum tumor marker, CAM 123-6, highly specific to pulmonary adenocarcinoma. Jpn J Cancer Res 1994; 85:211-219.
29. Sekine H, Ohno T, Kufe DW: Purification and characterization of a high molecular weight glycoprotein detectable in human milk and breast carcinomas. J Immunol 1985; 135: 3610-3615.
30. Cordell J, Richardson TC, Pulford KA, Ghosh AK, Getter KC, Hyderman E et al: Production of monoclonal antibodies against human epithelial membrane antigen for use in diagnostic immunocytochemistry. Br J Cancer 1985; 52:347-354.
31. ten Berge EL, Snijdewint FG, von Mensdorff-Pouilly S, Poort-Keesom RJ, Oudejans JJ, Meijer JW et al: MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form. J Clin Pathol 2001; 54:933-939.
32. Tang W, Guo Q, Usuda M, Kokudo N, Seyama Y, Minagawa M et al: Histochemical expression of sialoglycoconjugates in carcinoma of the papilla of Vater. Hepato-gastroenterology 2005; 52:67-71.
33. Inagaki Y, Tang W, Guo Q, Kokudo N, Sugawara Y, Karako H et al: Sialoglycoconjugates expression in primary colorectal cancer and metastatic lymph node tissues. Hepato-Gastroenterology 2007; 54:53-57.
34. Kongtawelert P, Tangkijvanich P, Ong-Chai S, Poovorawan Y: Role of serum total sialic acid in differentiating cholangicarcinoma from hepatocellular carcinoma. World J Gastroenterol 2003; 9:2178-2181.
35. Juntavee A, Sripa B, Pugkhem A, Khuntikeo N, Wongkham S: Expression of sialyl Lewis(a) relates to poor prognosis in cholangiocarcinoma. World J Gastroenterol 2005; 11:249-254.